Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Leadership Team

- Leonard S. Schleifer, MD, PhD
  President and Chief Executive Officer
  + Fellow, American Association for the Advancement of Science (AAAS)

- George D. Yancopoulos, MD, PhD
  President and Chief Scientific Officer
  + Member, National Academy of Sciences

- P. Roy Vagelos, MD
  Chairman of the Board
  + Former Chief Executive Officer and Chairman of the Board, Merck & Co.
  + Member, National Academy of Sciences

- Board of Directors includes two Nobel Laureates and seven members of the National Academy of Sciences

Locations

- Tarrytown, NY: Corporate and Research & Development headquarters
- Rensselaer, NY and Limerick, Ireland: Large-scale biologics Industrial Operations and Product Supply (IOPS) facilities
- Dublin, Ireland and London, UK: Global business offices

General Company Information

- Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
- More than 9,000 employees in the U.S., UK and EU
- 2020 R&D investment of $2.7 billion

FDA-Approved & Marketed Medicines*

1. **Arcalyst** (rilonacept)
   Injection for Subcutaneous Use

2. **DUPIXENT** (dupilumab)
   Injection 200mg, 300mg

3. **Evkeeza**
   (evinacumab-drgn)
   Injection

4. **EYLEA**
   (aflibercept)
   Injection

5. **Inmazeb**
   (atoltivimab, maftivimab, and odesivimab-ebgn)

6. **KEVZARA**
   (sarilumab)
   Injection

7. **LIBTAYO**
   (cemiplimab-rwlc)
   Injection

8. **Praluent**
   (alirocumab)
   Injection

9. **ZALTRAP**
   (ziv-aflibercept)

* In collaboration with Sanofi outside of U.S. For Praluent, in collaboration with Sanofi prior to April 2020; effective April 2020, Regeneron is solely responsible for the U.S. development and commercialization and Sanofi is solely responsible for the ex-U.S. development and commercialization of Praluent.

* In collaboration with Bayer outside of U.S. | Marketed by Sanofi. | Marketed by Kiniksa Pharmaceuticals.

* U.S. Food and Drug Administration
Clinical Product Candidates

### PHASE 1

<table>
<thead>
<tr>
<th>Drug Candidate</th>
<th>Indication</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>FIANLIMAB</td>
<td>LAG-3 Antibody (Solid tumors, advanced hematologic malignancies)</td>
<td></td>
</tr>
<tr>
<td>REGN569</td>
<td>GITR Antibody (Cancer)</td>
<td>Stable</td>
</tr>
<tr>
<td>ODRONEXTAMAB</td>
<td>CD20 x CD3 Antibody (Cancer)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN4018</td>
<td>MUC16 x CD28 Antibody (Cancer)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN5459</td>
<td>BCMA x CD3 Antibody (Cancer)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN5678</td>
<td>PSCA x CD28 Antibody (Cancer)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN7075</td>
<td>ESFR x CD28 Antibody (Cancer)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN6490</td>
<td>IL-36b Antibody (Palmar-plantar pustulosis)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN7257</td>
<td>IL2Rg Antibody (Aplastic anemia)</td>
<td>Stable</td>
</tr>
</tbody>
</table>

In collaboration with:
- Sanofi
- Takeda
- Mitsubishi Tanabe
- Bayer
- Intella
- Alnylam
- Roche

### PHASE 2

<table>
<thead>
<tr>
<th>Drug Candidate</th>
<th>Indication</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABLFIBRECEPT</td>
<td>VEGF-Trap (High dose (mg) for wet age-related macular degeneration (AMD))</td>
<td>Stable</td>
</tr>
<tr>
<td>CASIRIVIMAB+IMDEVIMAB</td>
<td>SARS-CoV-2 Virus Multi-Antibody Therapy (SARS-CoV-2 safety study)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN5668</td>
<td>MUC16 x CD28 Antibody (Cancer)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN7075</td>
<td>ESFR x CD28 Antibody (Cancer)</td>
<td>Stable</td>
</tr>
<tr>
<td>NTLA-2001</td>
<td>CRISPRI/Cas9 (Hereditary transthyretin amyloidosis with polyneuropathy)</td>
<td>Stable</td>
</tr>
<tr>
<td>ALN-HSD</td>
<td>REGN7071 (Flata Therapeutic Nonalcoholic steatohepatitis)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN5458</td>
<td>BCMA x CD3 Antibody (Multiple myeloma)</td>
<td>Stable</td>
</tr>
</tbody>
</table>

### PHASE 3

<table>
<thead>
<tr>
<th>Drug Candidate</th>
<th>Indication</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABLFIBRECEPT</td>
<td>VEGF-Trap (Heterozygous familial hypercholesterolemia (HeFH) in pediatrics)</td>
<td>Stable</td>
</tr>
<tr>
<td>CEMIPLIMAB</td>
<td>PD-1 Antibody (Metastatic or locally advanced cutaneous squamous cell carcinoma, (CSCC), neoadjuvant CSCC, second-line cervical cancer)</td>
<td>Stable</td>
</tr>
<tr>
<td>CEMDISIRAN</td>
<td>CS RNAI Therapeutic Immunoglobulin A nephropathy</td>
<td>Stable</td>
</tr>
<tr>
<td>CARISIRIVIMAB+IMDEVIMAB</td>
<td>SARS-CoV-2 Virus Multi-Antibody Therapy (Treatment in non-hospitalized COVID-19 patients)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN4461</td>
<td>LEPR Agonist Antibody (Generalized lipodysphasia)</td>
<td>Stable</td>
</tr>
<tr>
<td>EVINACUMAB</td>
<td>ANGPTL-3 Antibody (Severe hypertriglyceridemia)</td>
<td>Stable</td>
</tr>
<tr>
<td>GARETOSMAB</td>
<td>Activin-A Antibody (Fibroblastosis Osilifarian)</td>
<td>Stable</td>
</tr>
<tr>
<td>REGN5458</td>
<td>BCMA x CD3 Antibody (Multiple myeloma)</td>
<td>Stable</td>
</tr>
</tbody>
</table>

### Leaders in Technology

**Fully human monoclonal antibodies**

Regeneron has developed a suite of patented technologies (VelociSuite®, including VelociGene®, Velocimmune® and VelociMab®), that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

**Fusion proteins**

Our novel and patented “Trap” fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

**Regeneron Genetics Center®**

A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

---

**Fast Company: Best Workplaces for Innovators, 2021**

**Great Place To Work: Fortune 100 Best Companies to Work For, 2021**

**Great Place to Work Ireland: Best Workplaces for Women, 2021**

**Fast Company: World Changing Ideas (Pandemic Response), 2021**

**IDEA Pharma: Pharmaceutical Invention Index, 2021**

**Science: Top Employer, 2020**

---

**Fortune: Change the World, 2020**

**Forbes: JUST Companies, 2020**

**Newsweek: America’s Most Responsible Companies, 2020**

**Dow Jones Sustainability World Index, 2020**

**Dow Jones Sustainability North America Index, 2020**

**Civic 50: Most Community-Minded Companies in the Nation, 2020**

**Shingo Institute: The Shingo Prize, 2019**

---

To learn more about us, please visit:

REGENERON.COM  @REGENERON

© Regeneron Pharmaceuticals, Inc. 8/21